Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Imaging-Based Prediction Of Molecular Therapy Targets In NSCLC By Radiogenomics And AI Approaches: A Systematic Review

G. Ninatti, M. Kirienko, E. Neri, M. Sollini, A. Chiti
Published 2020 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
The objective of this systematic review was to analyze the current state of the art of imaging-derived biomarkers predictive of genetic alterations and immunotherapy targets in lung cancer. We included original research studies reporting the development and validation of imaging feature-based models. The overall quality, the standard of reporting and the advancements towards clinical practice were assessed. Eighteen out of the 24 selected articles were classified as “high-quality” studies according to the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2). The 18 “high-quality papers” adhered to Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD) with a mean of 62.9%. The majority of “high-quality” studies (16/18) were classified as phase II. The most commonly used imaging predictors were radiomic features, followed by visual qualitative computed tomography (CT) features, convolutional neural network-based approaches and positron emission tomography (PET) parameters, all used alone or combined with clinicopathologic features. The majority (14/18) were focused on the prediction of epidermal growth factor receptor (EGFR) mutation. Thirty-five imaging-based models were built to predict the EGFR status. The model’s performances ranged from weak (n = 5) to acceptable (n = 11), to excellent (n = 18) and outstanding (n = 1) in the validation set. Positive outcomes were also reported for the prediction of ALK rearrangement, ALK/ROS1/RET fusions and programmed cell death ligand 1 (PD-L1) expression. Despite the promising results in terms of predictive performance, image-based models, suffering from methodological bias, require further validation before replacing traditional molecular pathology testing.
This paper references
A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)
Y. Shi (2014)
Identifying epidermal growth factor receptor mutation status in patients with lung adenocarcinoma by three-dimensional convolutional neural networks.
Jun-feng Xiong (2018)
First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
B. Solomon (2014)
Validated imaging biomarkers as decision-making tools in clinical trials and routine practice: current status and recommendations from the EIBALL* subcommittee of the European Society of Radiology (ESR)
N. deSouza (2019)
Predictive radiogenomics modeling of EGFR mutation status in lung cancer
O. Gevaert (2017)
PD-L1 expression testing in non-small cell lung cancer
C. Teixidó (2018)
Radiomics and liquid biopsy in oncology: the holons of systems medicine
E. Neri (2018)
EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII).
A. Midha (2015)
Advanced-Stage Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018.
J. Remon (2019)
Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisions
C. Mayo-de-las-Casas (2017)
Assessing EGFR gene mutation status in non-small cell lung cancer with imaging features from PET/CT.
Mengmeng Jiang (2019)
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.
L. Sequist (2013)
Tracking tumor biology with radiomics: A systematic review utilizing a radiomics quality score.
S. Sanduleanu (2018)
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
Y. Wu (2017)
Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA
J. Remon (2017)
Computed Tomography Imaging Characteristics of Non-Small-Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangements: A Systematic Review and Meta-Analysis.
D. Mendoza (2019)
Liquid biopsy in the era of immune-oncology. Is it ready for prime-time use for cancer patients?
P. Hofman (2019)
Value of pre-therapy 18F-FDG PET/CT radiomics in predicting EGFR mutation status in patients with non-small cell lung cancer
J. Zhang (2019)
Poor reporting of multivariable prediction model studies: towards a targeted implementation strategy of the TRIPOD statement
P. Heus (2018)
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
T. Mok (2009)
Radiomics signature: A potential and incremental predictor for EGFR mutation status in NSCLC patients, comparison with CT morphology.
Wenting Tu (2019)
Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecula
G. Kalemkerian (2018)
Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.
J. Mazieres (2015)
Artificial intelligence versus clinicians: systematic review of design, reporting standards, and claims of deep learning studies
M. Nagendran (2020)
Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer
J. Soria (2018)
Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
T. Hida (2017)
The Potential of Radiomics Nomogram in Non-invasively Prediction of Epidermal Growth Factor Receptor Mutation Status and Subtypes in Lung Adenocarcinoma
W. Zhao (2019)
The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping.
A. Zwanenburg (2020)
Imaging of Precision Therapy for Lung Cancer: Current State of the Art.
Hyesun Park (2019)
Toward automatic prediction of EGFR mutation status in pulmonary adenocarcinoma with 3D deep learning
W. Zhao (2019)
First‐Line Nivolumab in Stage IV or Recurrent Non–Small‐Cell Lung Cancer
D. Carbone (2017)
Predictive Power of a Radiomic Signature Based on 18F-FDG PET/CT Images for EGFR Mutational Status in NSCLC
X. Li (2019)
First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.
J. Han (2012)
Quality of science and reporting of radiomics in oncologic studies: room for improvement according to radiomics quality score and TRIPOD statement
J. Park (2019)
Towards clinical application of image mining: a systematic review on artificial intelligence and radiomics
M. Sollini (2019)
The Clinical Impact of Comprehensive Genomic Testing of Circulating Cell‐Free DNA in Advanced Lung Cancer
S. Laufer-Geva (2018)
Decoding tumor mutation burden and driver mutations in early stage lung adenocarcinoma using CT‐based radiomics signature
Xiao-xiao Wang (2019)
Deep Learning: A Primer for Radiologists.
G. Chartrand (2017)
A novel radiomic nomogram for predicting epidermal growth factor receptor mutation in peripheral lung adenocarcinoma.
Xiaoqian Lu (2020)
Radiomics for the Prediction of EGFR Mutation Subtypes in Non-small-cell Lung Cancer.
S. Li (2019)
Somatic Mutations Drive Distinct Imaging Phenotypes in Lung Cancer.
E. Rios Velazquez (2017)
The Value of Liquid Biopsies for Guiding Therapy Decisions in Non-small Cell Lung Cancer
J. Saarenheimo (2019)
Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): The TRIPOD Statement
Gary S. Collins (2015)
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.
N. Rizvi (2015)
CT Slice Thickness and Convolution Kernel Affect Performance of a Radiomic Model for Predicting EGFR Status in Non-Small Cell Lung Cancer: A Preliminary Study
Y. Li (2018)
An introduction to ROC analysis
T. Fawcett (2006)
Radiogenomics: creating a link between molecular diagnostics and diagnostic imaging.
Aaron M Rutman (2009)
Radiomics: Images Are More than Pictures, They Are Data
R. Gillies (2016)
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
T. Mok (2019)
Brigatinib versus Crizotinib in ALK‐Positive Non–Small‐Cell Lung Cancer
R. Camidge (2018)
Quantitative Biomarkers for Prediction of Epidermal Growth Factor Receptor Mutation in Non-Small Cell Lung Cancer
L. Zhang (2018)
ALK molecular phenotype in non-small cell lung cancer: CT radiogenomic characterization.
S. Yamamoto (2014)
Crizotinib in ROS1-rearranged non-small-cell lung cancer.
A. Shaw (2014)
The prevalence of programmed death ligand-1 (PD-L1) expression in non-small cell lung cancer in an unselected, consecutive population
B. G. Skov (2019)
Computed Tomography-Based Radiomics Signature: A Potential Indicator of Epidermal Growth Factor Receptor Mutation in Pulmonary Adenocarcinoma Appearing as a Subsolid Nodule.
Xinguan Yang (2019)
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
Jean-Charles Soria (2017)
2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up.
J. Vansteenkiste (2014)
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
M. Maemondo (2010)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
F. Bray (2018)
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
A. Drilon (2019)
The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis
Yue-lun Zhang (2016)
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
F. Barlési (2016)
Receiver operating characteristic curve in diagnostic test assessment.
J. Mandrekar (2010)
Pembrolizumab for the treatment of non-small-cell lung cancer.
E. Garon (2015)
ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.
A. Shaw (2019)
Assessing PD-L1 Expression Level by Radiomic Features From PET/CT in Nonsmall Cell Lung Cancer Patients: An Initial Result.
Mengmeng Jiang (2019)
Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)
S. Dearden (2013)
Radiogenomics: bridging imaging and genomics
Z. Bodalal (2019)
Heterogeneity of PD-L1 expression in non-small cell lung cancer: Implications for specimen sampling in predicting treatment response
A. Haragan (2019)
Utility of CT radiomics for prediction of PD‐L1 expression in advanced lung adenocarcinomas
Jiyoung Yoon (2020)
Methodologic Guide for Evaluating Clinical Performance and Effect of Artificial Intelligence Technology for Medical Diagnosis and Prediction.
S. Park (2018)
Usefulness of gradient tree boosting for predicting histological subtype and EGFR mutation status of non-small cell lung cancer on 18F FDG-PET/CT
S. Koyasu (2019)
PET Radiomics in NSCLC: state of the art and a proposal for harmonization of methodology
M. Sollini (2017)
Are liquid biopsies a surrogate for tissue EGFR testing?
J. Goldman (2018)
Erlotinib in previously treated non-small-cell lung cancer.
F. Shepherd (2005)
Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience
L. Sholl (2015)
Durvalumab for the treatment of non-small cell lung cancer
S. Murakami (2019)
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.
N. Lindeman (2018)
Identifying EGFR mutations in lung adenocarcinoma by noninvasive imaging using radiomics features and random forest modeling
Tian-ying Jia (2019)
A survey on deep learning in medical image analysis
G. Litjens (2017)
Non-invasive tumor genotyping using radiogenomic biomarkers, a systematic review and oncology-wide pathway analysis
Robin W Jansen (2018)
Decoding Tumor Phenotypes for ALK, ROS1, and RET Fusions in Lung Adenocarcinoma Using a Radiomics Approach
Hyun Jung Yoon (2015)
Genomics of non-small cell lung cancer (NSCLC): Association between CT-based imaging features and EGFR and K-RAS mutations in 122 patients-An external validation.
S. Rizzo (2019)
Predicting EGFR mutation status in lung adenocarcinoma on computed tomography image using deep learning
S. Wang (2019)
Quantitative imaging biomarkers in nuclear medicine: from SUV to image mining studies. Highlights from annals of nuclear medicine 2018
M. Sollini (2019)
Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers
S. Dogan (2012)
PET/CT radiomics in breast cancer: mind the step.
M. Sollini (2020)
Liquid Biopsy for Advanced Non‐Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
C. Rolfo (2018)
Detection of epithelial growth factor receptor (EGFR) mutations on CT images of patients with lung adenocarcinoma using radiomics and/or multi-level residual convolutionary neural networks.
X. Li (2018)
Interdisciplinarity: An essential requirement for translation of radiomics research into clinical practice -a systematic review focused on thoracic oncology.
M. Sollini (2020)
Reporting of artificial intelligence prediction models
G. Collins (2019)
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
S. Patel (2015)
Atezolizumab for First‐Line Treatment of Metastatic Nonsquamous NSCLC
M. Socinski (2018)
Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort
O. Gautschi (2015)

This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar